rss
Heart 2009;95:1103-1107 doi:10.1136/hrt.2008.162800
  • Original article
  • Systemic disease and the heart

Effects of enzyme-replacement therapy in patients with Anderson–Fabry disease: a prospective long-term cardiac magnetic resonance imaging study

  1. M Imbriaco1,
  2. A Pisani2,
  3. L Spinelli3,
  4. A Cuocolo1,
  5. G Messalli1,
  6. E Capuano1,
  7. M Marmo1,
  8. R Liuzzi4,
  9. B Visciano2,
  10. B Cianciaruso2,
  11. M Salvatore1
  1. 1
    Department of Biomorphological and Functional Sciences, University “Federico II,” Naples, Italy
  2. 2
    Department of Nephrology, University “Federico II,” Naples, Italy
  3. 3
    Department of Clinical Medicine, Cardiovascular and Immunological Sciences, University “Federico II,” Naples, Italy
  4. 4
    Department of National Research Council (IBB-CNR), University “Federico II,” Naples, Italy
  1. Dr M Imbriaco, Via Posillipo 196, 80123, Naples, Italy; mimbriaco{at}hotmail.com
  • Accepted 7 April 2009
  • Published Online First 15 April 2009

Abstract

Background: Anderson–Fabry disease is a multisystem X linked disorder of lipid metabolism frequently associated with cardiac symptoms, including left ventricular (LV) hypertrophy gradually impairing cardiac function. Evidence showing that enzyme-replacement therapy (ERT) can be effective in reducing LV hypertrophy and improving myocardial function in the long term is limited.

Objective: This study aimed to assess the long-term effects of ERT with recombinant α-galactosidase A (agalsidase beta, Fabrazyme) on LV function and myocardial signal intensity in 11 patients with Anderson–Fabry disease.

Patients: Eleven patients (eight males, three females) with varying stages of genetically confirmed Anderson–Fabry disease were examined by means of physical examination and magnetic resonance imaging before ERT with agalsidase beta at 1 mg/kg every other week (study 1) and after a mean treatment duration of 45 months (study 2).

Results: At 45 months of treatment, LV mass and LV wall thickness had significantly reduced: 188 (SD 60) g versus 153 (47) g, and 16 (4) mm versus 14 (4) mm, respectively. Furthermore, a significant reduction in myocardial T2 relaxation times was noted in all myocardial regions, that is, interventricular septum 80 (5) ms versus 66 (8) ms, apex 79 (10) ms versus 64 (10) ms, and lateral wall 80 (8) ms versus 65 (16) ms. Changes in LV ejection fraction were not significant. Amelioration of clinical symptoms was observed in all patients.

Conclusions: Long-term therapy with agalsidase beta at 1 mg/kg every 2 weeks was effective in significantly reducing LV hypertrophy, improving overall cardiac performance and ameliorating clinical symptoms in patients with Anderson–Fabry disease.

Footnotes

  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by University Federico II, Naples, Italy.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. hrt.2008.162800v1
    2. 95/13/1103 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Latest from Education in Heart

Latest from Education in Heart

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Heart.
View free sample issue >>

Free archive
The full back archive is now available for Heart. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.